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Abstract
Reports of methamphetamine-related emergency room visits suggest that elevated body 
temperature is a universal presenting symptom, with lethal overdoses generally associated with 
extreme hyperthermia. This review summarizes the available information on methamphetamine 
toxicity as it pertains to elevations in body temperature. First, a brief overview of 
thermoregulatory mechanisms is presented. Next, central and peripheral targets that have been 
considered for potential involvement in methamphetamine hyperthermia are discussed. Finally, 
future areas of investigation are proposed, as further studies are needed to provide greater insight 
into the mechanisms that mediate the alterations in body temperature elicited by 
methamphetamine.
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1. Introduction
A number of excellent reviews are available outlining the health and societal concerns 
stemming from methamphetamine (METH) abuse and overdose (Davidson et al., 2001; 
Cruickshank & Dyer, 2009; Krasnova & Cadet, 2009; Clark et al., 2012; Marshall & O’Dell, 
2012), yet there remains a paucity of information related to the hyperthermic effects of 
METH. In the United States, METH use is responsible for an estimated 94,000 emergency 
department admissions annually (NIDA, 2011), with elevated body temperature appearing 
as a universal presenting symptom. METH-induced hyperthermia puts individuals at risk for 
death and there are few treatment options (Greenblatt & Osterberg, 1961; Schep et al., 
2010). Consequently, this review focuses on METH hyperthermia. It covers what is known 
about the effects of METH on body temperature as well as providing a review of the 
literature on previously tested hypotheses concerning METH hyperthermia and the 
outcomes of these studies. Finally, the review suggests directions for future research.
2. Temperature regulation
The regulation of body temperature requires a coordinated effort between central and 
peripheral mechanisms, with the balance of heat retention and dissipation representing key 
components of the process. Since pathophysiology results from the disruption of normal 
physiological functions, understanding how METH may dysregulate body temperature to 
cause hyperthermia requires a better understanding of how normal temperature regulation 
occurs, a topic which is briefly reviewed herein. Normal heat loss mechanisms, such as 
those triggered in response to high ambient temperatures, include: 1) radiation, 2) 
conduction, 3) convection, and 4) evaporation (Docherty & Green, 2010). The first three 
processes involve the passive transfer of heat and energy from the body to the colder 
surrounding environment, while evaporation is an active process that occurs primarily in the 
form of sweating (or panting in animals).
Normal heat generating mechanisms, such as those triggered in response to cold 
environments, include: 1) increased metabolic activity of tissues (e.g., increased tissue 
oxidation), 2) increased muscle activity (e.g., through shivering, exercise), and 3) 
nonshivering thermogenesis (e.g., through increased lipid and carbohydrate metabolism, 
brown adipose tissue) (Cannon & Nedergaard, 2004; Docherty & Green, 2010; Morrison & 
Nakamura, 2011). Additional heat retention strategies include: 1) vasoconstriction (to 
minimize heat loss by radiation), and 2) insulation (through fat under the skin, piloerection 
in animals with fur) (Docherty & Green, 2010; Morrison & Nakamura, 2011).
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2.1. Anatomy of temperature regulation
Physiological responses used to maintain body temperature are regulated by an integration 
of central nervous system (CNS) and systemic events, with coordination of these processes 
primarily controlled in the hypothalamus (Morrison & Nakamura, 2011). Heat and cold are 
detected by temperature sensors in the body, which are located in both the periphery and 
CNS. The peripheral sensors are found in the skin and utilize transient receptor potential 
(TRP) channels on primary sensory afferents to relay information to the CNS, and ultimately 
the hypothalamus (Morrison & Nakamura, 2011). Once this information reaches the 
hypothalamus, warm-sensitive neurons in the anterior preoptic area respond to changes in 
temperature, which are sensed locally in the tissue (Nakayama et al., 1961).
Neurons in the preoptic area of the hypothalamus have synaptic contacts that: 1) activate 
parasympathetic neurons in the anterior hypothalamus, and 2) inhibit sympathetic neurons in 
the posterior hypothalamus. Thus, when an increase in temperature is sensed, vasodilation 
and sweating result due to parasympathetic stimulation and removal of sympathetic tone to 
blood vessels in the skin (Charkoudian, 2003; Rusyniak & Sprague, 2006). Other 
physiological responses that occur in an effort to dissipate heat include decreased metabolic 
and muscle activity (Webb, 1995).
Although the hypothalamus is recognized as the thermoregulatory center that coordinates the 
information coming in from the periphery via the primary sensory afferents with the out-
going responses to the autonomic nervous system, other intervening brain regions may also 
participate in this coordinated response. These regions include the lateral parabrachial 
nucleus and the rostral ventromedial medulla (Morrison & Nakamura, 2011).
2.2. Neurochemistry of temperature regulation
The major neurotransmitters involved in thermoregulation are: glutamate (afferents to the 
hypothalamus and some efferents), γ-aminobutyric acid (GABA; efferents from the 
hypothalamus), serotonin (brainstem neurons), norepinephrine and acetylcholine (autonomic 
neurons) (Morrison & Nakamura, 2011). In addition, a number of peptides, hormones, and 
cytokines can modulate body temperature (Morrison & Nakamura, 2011). The sources of 
these bioactive molecules are varied and include neurons, glia, myocytes (cardiac and 
skeletal muscle), endothelial cells, and blood cells (Kiyatkin & Sharma, 2009).
2.3. Body mass scaling
A major challenge for research on hyperthermia and thermoregulatory processes is 
appropriate extrapolation of data from studies in animals to humans (Gordon, 2007). Most 
studies involving the hyperthermic effect of METH have been conducted in rodents, with 
issues related to body mass scaling being of particular concern. The vasomotor index, which 
quantifies the extent to which an animal can regulate its surface temperature, is positively 
correlated with body mass (Phillips & Heath, 1995). Smaller animals, such as rodents, have 
a large surface area:volume ratio compared to humans, and use different strategies to 
regulate surface temperature. Small animals rely on passive heat dissipation and alterations 
in metabolic rate to achieve control, whereas large animals, such as humans, have smaller 
surface area:volume available for heat exchange and depend on sweating and peripheral 
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vasomotor mechanisms to regulate this process, rather than alterations in metabolic rate 
(Gordon, 2007). A major consequence of these differences is that rodents, with their small 
size relative to humans, are more vulnerable to fluctuations in ambient temperature than 
humans.
3. METH and temperature regulation
METH acts as an indirect agonist that can cause the release of monoamines and inhibit their 
reuptake in both the CNS and periphery (Davidson et al., 2001; Krasnova & Cadet, 2009; 
Schep et al., 2010). At lower, stimulant doses, METH does not have significant effects on 
body temperature, but can produce lethal hyperthermia upon exposure to high doses 
(Albertson et al., 1999; Krasnova & Cadet, 2009). Information on general thermoregulatory 
mechanisms that are affected by METH are summarized, followed by an overview of 
environmental factors and disease states that can modulate the effect of METH on body 
temperature.
3.1. Body temperature dysregulation by METH
The mechanisms through which METH affects body temperature include both central and 
peripheral targets (Fig. 1). In general, METH increases body temperature by promoting heat 
generation and retention, and suppressing responses that would facilitate heat dissipation 
(Table 1). It should be noted that these effects can vary greatly by species (e.g., rats vs. 
mice).
As a psychomotor stimulant, METH causes increased activation of and metabolism in the 
CNS and skeletal muscles (Estler, 1975; Makisumi et al., 1998), which may elevate brain 
and body temperature. In addition, METH causes vasoconstriction (Gordon et al., 1991; 
Turnipseed et al., 2003; Watts & McCollester, 2006; Haning & Goebert, 2007), which can 
contribute to the ensuing hyperthermia by preventing heat dissipation in the periphery. In 
laboratory animals, piloerection may also indicate that heat dissipation mechanisms have 
become compromised and/or heat retention mechanisms are activated by METH, although it 
should be cautioned that serotonin release can cause piloerection unrelated to body 
temperature (Gordon, 1983, 2005). These heat generating processes more often than not 
overwhelm some efforts by METH-treated laboratory animals to dissipate heat, including 
pronounced drooling and saliva spreading (Morrison & Nakamura, 2011).
3.2. Modulators of thermoregulation and METH hyperthermia
A number of environmental factors and disease states can affect temperature regulation, with 
the ones most relevant to the conditions under which METH exposure may occur 
summarized here. Primary amongst them is ambient temperature, where increasing or 
decreasing environmental temperature can greatly enhance or reduce METH’s effects on 
body temperature, respectively (Bowyer et al., 1992, 1994). In METH-treated animals, 
elevations in brain temperature have also been reported at increased ambient temperatures 
(Brown & Kiyatkin, 2005; Kiyatkin & Sharma, 2011, 2012). In humans, prolonged exposure 
to excessive environmental temperatures can cause hyperthermia and death, with 65% of 
heat-related deaths resulting from exposure to excessive heat (CDC, 2006); this clinical 
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condition would be expected to be greatly exaggerated with co-exposure to METH, as has 
been shown to be the case for 3,4-methylenedioxymethamphetamine (MDMA) (Green et al., 
2004; Kiyatkin & Sharma, 2012). In contrast, cold environments can prevent METH-
induced hyperthermia and attenuate resulting METH-induced increases in oxidation 
products and neurotoxicity (Bowyer et al., 1994; LaVoie & Hastings, 1999; also see below).
Social interaction can also affect body temperature. Earlier studies have reported increases 
in body and brain temperature following exposure to conspecifics (Kiyatkin et al., 2002). 
Many studies have shown that exposure of animals to METH when group housed greatly 
enhances the toxicity and lethality of the drug, a phenomenon also known as “aggregate 
toxicity” (Greenblatt & Osterberg, 1961). The changes in body temperature may be 
secondary to arousal-induced neuronal activation since alterations in brain temperature 
precede and exceed those measured in the body, including head muscles adjacent to the skull 
(Brown et al., 2003). However, an alternate explanation could relate to the higher energy 
demands of the brain compared to other tissues, which would be expected to generate heat 
(Kiyatkin, 2007). Regardless of the underlying mechanisms of the aforementioned, 
hyperthermia resulting from social interactions has been reported to enhance the toxicity 
produced by METH by increasing the duration of the hyperthermia (Brown et al., 2003).
Exercise can also elevate body temperature, by increasing cardiac and skeletal muscle 
activity (Wendt et al., 2007). In humans, brain and body core temperature rise in parallel in 
response to exercise (Nybo, 2012). Further increases in body temperature that occur in 
association with METH can thus exacerbate exercise-induced heat stress on the body. These 
observations have practical relevance as well in situations where the amphetamines are used 
clinically. Children and adults with attention deficit hyperactivity disorder (ADHD) are 
treated with a mixture of amphetamine salts (e.g., Adderall) and may therefore be prone to 
more difficulty in extreme temperature situations (e.g., participating in sports during the hot 
summer months).
Stressor exposures in combination with METH can also modulate body temperature in rats 
and mice. For example, unpredictable stress in rats enhances the hyperthermia produced by 
METH (Tata et al., 2007). METH-induced extracellular dopamine concentration in stressed 
vs. unstressed rats does not differ significantly, suggesting the contribution of non-
dopaminergic systems in these effects (Tata et al., 2007). In contrast, serotonergic function 
appears important because the enhancement of METH-induced hyperthermia by stress can 
be prevented by the 5-HT2 antagonist ketanserin (Doyle & Yamamoto, 2010). This is 
consistent with the well-established up-regulation of 5-HT2 receptor expression induced by 
various forms of stress (Davis et al., 1995; Takao et al., 1995; Ossowska et al., 2001; 
Matuszewich & Yamamoto, 2003). This stress-induced alteration would be expected to 
enhance the hyperthermic effects mediated through METH-induced release of serotonin 
(Doyle & Yamamoto, 2010). In contrast to these data obtained in rats, mice exposed to 
restraint stress in combination with METH show markedly decreased body temperature and 
resistance to METH-induced dopaminergic neurotoxicity (Miller & O’Callaghan, 1994).
In addition to the aforementioned environmental factors, a number of disease states have 
been documented to increase the risk of developing hyperthermia. These include: 
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cardiovascular disease (e.g., chronic ischemic heart disease); endocrine, nutritional, and 
metabolic disorders (e.g., diabetes); infection and psychiatric disorders (CDC, 2006). The 
extent to which they may be extrapolated to METH-induced hyperthermia remains under 
investigation.
All of these factors are important to keep in mind because METH hyperthermia in humans 
generally involves an interaction between exposure to the drug and one or more of these 
exacerbating factors.
4. Clinical pharmacology and considerations related to METH hyperthermia
An overview of the pharmacokinetics of METH that are relevant for understanding its 
effects on body temperature are reviewed. In addition, the clinical management of METH 
hyperthermia is presented, along with select clinical consequences that can result from the 
hyperthermic effects of METH.
4.1. Pharmacokinetic parameters of METH
As dose to target is an important component of toxicity, the pharmacokinetics of METH are 
important to understand because different routes of administration can affect the amount of 
METH getting to the target, thereby affecting the magnitude of effects and their duration of 
action. METH is used through four primary routes of administration: 1) intravenous, 2) 
smoking, 3) oral, and 4) intranasal. Route of use dictates bioavailability, with studies 
demonstrating oral administration resulting in the lowest (67%) and intravenous 
administration resulting in the highest (100%) absorption (Schep et al., 2010). Intranasal 
(79%) and smoking (67–90%), depending on technique utilized, fall in between in 
bioavailability (Cruickshank & Dyer, 2009). Route of administration also affects the time to 
peak effect. For example, in preclinical studies in rhesus macaques, a similar peak 
temperature, but delayed onset is observed when METH is administered orally compared to 
intraperitoneally (Crean et al., 2006, 2007). In humans, intravenous and intranasal dosing 
results in peak effects within 15 minutes, while smoking has a slightly longer time-to-peak 
of 18 minutes and lastly, oral uptake results after a significant delay of approximately 3 
hours (Cruickshank & Dyer, 2009). Alternative routes of administration, for which little to 
no pharmacokinetic data exist, have emerged in recent years and require further 
investigation to elucidate drug uptake. These include body stuffing in which poorly 
packaged drugs are ingested, usually in an attempt to avoid prosecution by the police; 
‘parachuting’ in which the drug is placed into a plastic bag with the seal removed, rolled 
tightly, and swallowed, theoretically releasing the drug over a prolonged period; and 
‘shelving’, also known as intravaginal stuffing (Hendrickson et al., 2006; Kashani & Ruha, 
2004; West et al., 2010). Although administration routes of METH that lead to greater 
bioavailability would be expected to result in increased hyperthermia in clinical situations, it 
is currently unclear if maximum increases in METH-induced hyperthermia are specifically 
related to peak plasma concentration, or if increases in body temperature are more related to 
cumulative exposure.
The metabolism of METH occurs primarily in the liver through three main processes: 1) N-
demethylation via cytochrome P450 2D6, 2) aromatic hydroxylation through cytochrome 
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P450 2D6, and 3) β-hydroxylation, producing amphetamine, 4-hydroxymethamphetamine, 
and norephedrine, respectively (Schep et al., 2010). Some of these metabolites may 
contribute to sustained hyperthermic effects of METH, with amphetamine reported to 
produce elevations in body temperature on its own (Levi et al., 2012).
4.2. Treatment of METH hyperthermia
The major presenting symptom in emergency rooms involving a METH overdose is extreme 
hyperthermia that can be lethal if left untreated (Bowyer et al., 1984; Ito et al., 2008). Other 
presenting symptoms commonly observed, particularly in high-dose patients, include 
hypertension, tachycardia, dyspnea, and chest pain, with other features including increased 
agitation, altered mental status, pupil dilation, shivering, and possible seizure activity 
(Albertson et al., 1999). Medical interventions focus on strategies to minimize the 
bioavailability of METH and symptomatic management.
The clinical diagnosis of hyperthermia occurs when the core body temperature exceeds 40° 
C, at which point normal thermoregulatory mechanisms fail and the body is no longer 
capable of effectively dissipating heat (Bynum et al., 1978). Currently, no approved 
pharmacotherapy is available for treating the hyperthermic effects of METH. Administration 
of ammonium chloride or activated charcoal can assist in resolving METH-induced 
hyperthermia by increasing the excretion of METH from the body through acidification of 
the urine or prevention of the absorption of orally ingested METH, respectively (Suchard, 
2007). Cooling, which can be accomplished using either external or internal means, 
however, remains the primary method for the clinical treatment of hyperthermia. External 
cooling measures can include cool water submersion, misting accompanied by fans, or 
hypothermia blankets (Eyer & Zilker, 2007; Suchard, 2007). Medical providers must remain 
vigilant that skin cooling is not performed too quickly as rapid skin cooling produces 
shivering and vasoconstriction, which would minimize therapeutic benefit. Endovascular 
cooling, in which the temperature of the patient’s blood is lowered via a cooling catheter, 
while not generally deemed necessary, is capable of inducing rapid cooling while reducing 
the impact of shivering and vasoconstriction (Eyer & Zilker, 2007). While these methods 
have been shown to be beneficial in the treatment of hyperthermia for other disease states, 
currently it is unknown if these treatments result in better patient outcomes during METH 
overdose situations and no clear prospective studies have been conducted to determine their 
effectiveness.
4.3. Clinical consequences of METH hyperthermia
Hyperthermia can promote rhabdomyolysis, multi-organ failure, release of excitotoxic 
neurotransmitters, increased reactive oxygen species production, and heightened breakdown 
of cytoskeletal proteins (Eyer & Zilker, 2007; West et al., 2010). Hyperthermia elicited by 
METH per se has been implicated in a number of these effects and are reviewed below.
One of the major organs especially sensitive to the hyperthermic effects of METH is the 
liver. An early analysis on the clinical presentations of acute METH toxic reactions reported 
hepatitis as the second most common presenting complaint (Smith & Fischer, 1970); and 
more recently, a clinical report showed acute liver damage can occur following METH use 
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even in patients without viral hepatitis (Kamijo et al., 2002). In a rat model of binge METH 
exposure, further supporting that METH alone does cause acute liver damage, aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) levels were elevated along 
with hepatic histopathological findings (Halpin & Yamamoto, 2012). With regard to the 
mechanisms involved in METH-induced liver toxicity, an increase in formation of reactive 
oxygen species (ROS) and subsequent lipid peroxidation, reduced glutathione (GSH) 
depletion and mitochondrial dysfunction were observed in freshly isolated rat hepatocytes 
(Eskandari, 2014). Previous studies have shown that an increase in body temperature by 
itself can also instigate hepatotoxic effects, namely those related to oxidative stress and 
resulting lipid peroxidation and membrane damage (Skibba et al., 1990, 1991, 1997), and 
thus most likely contributes to the liver damage observed after METH exposure. Of note, 
exogenous increases in temperature significantly exacerbate METH-induced hepatotoxicity 
in vitro (da Silva et al., 2013). In addition, METH-induced hyperthermia has been shown to 
play a prominent role in facilitating the structural and cellular liver damage and increases in 
peripheral ammonia produced by METH in vivo (Halpin et al., 2014). Consequently, the 
hyperthermia appears to dramatically contribute to the severity of METH-induced liver 
damage. Further investigation, however, is required for more accurate extrapolations and 
determination of the extent to which METH-induced hyperthermia by itself is responsible 
for the METH-induced liver toxicity.
METH-induced damage to dopaminergic nerve terminals in rats and mice is also associated 
with elevated core temperature (Bowyer et al., 1994, 1995; O’Callaghan & Miller, 1994; 
Miller & O’Callaghan, 1994, 2003; O’Callaghan & Miller, 2002). After administration of 
METH, increasing core temperature by elevating ambient temperature results in exacerbated 
dopaminergic neurotoxicity in both mice and rats (Bowyer & Holson, 1995). Decreasing 
core temperature by pharmacological, genetic and/or physiological means in combination 
with METH exposure decreases neurotoxicity (Albers & Sonsalla, 1995). For example, in 
rats, increases in brain levels of METH have no effect on dopaminergic neurotoxicity if 
body temperature is lowered by reducing ambient temperature (Bowyer et al., 1994, 1995). 
In essence, exposure to METH confers a poikilothermic effect where any change in ambient 
temperature appears reflected in corresponding changes in body temperature (see Bowyer et 
al., 1995). As noted earlier, the mechanistic relationship between METH administration, 
hyperthermia, neurotoxicity and METH-associated hyperthermia and mortality has not been 
established. Thus, while elevated temperature appears to be an obligatory component of 
METH neurotoxicity, the mechanism(s) controlling this are unknown.
5. Pharmacological and molecular biological studies of METH hyperthermia
A number of the monoamines, including norepinephrine, dopamine, and serotonin, appear to 
be involved in thermoregulation (Lin et al., 1982, 1983; Sprague et al., 2007), and these 
same neurotransmitters are impacted by METH exposure. Consequently, pharmacological 
and molecular manipulations involving these systems have long been a focus in 
characterizing the nature of METH-induced hyperthermia (e.g., Ito et al., 2008; Makisumi et 
al., 1998; Metzger et al., 2000). Concurrently, the ability of many drugs with no recognized 
monoaminergic actions (e.g., pentobarbital, MK-801, ethanol, dantrolene) to successfully 
block METH hyperthermia (Makisumi et al., 1998; Miller & O’Callaghan, 1994) 
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underscores the complexities involved in determining and understanding the mechanisms 
involved in METH-induced hyperthermia. Accordingly, the following sections summarize 
data describing the ability of a variety of pharmacological (Table 2) and molecular 
biological manipulations, targeting monoaminergic and non-monoaminergic systems, to 
prevent or attenuate METH-induced hyperthermia. In addition, manipulations that have been 
ineffective against METH-induced body temperature changes are briefly mentioned.
5.1. Monoaminergic systems – Norepinephrine, dopamine, and serotonin
The monoaminergic actions of METH in the CNS are well known, have been thoroughly 
characterized, and are the subject of a number of reviews (e.g., see Bowyer & Holson, 
1995). High dose exposure protocols of METH and related compounds cause the release of 
large amounts of dopamine, serotonin and norepinephrine accompanied by monoamine 
oxidase inhibition and a subsequent decrease in the monoamines themselves and their 
metabolites. A variety of methods have been utilized in trying to understand the role of the 
various monoamine systems in METH-induced hyperthermia and include: 1) direct injection 
of the monoamines into various brain areas involved in temperature regulation, 2) depletions 
of monoamines in general or in specific pools, 3) application of agonists or antagonists of 
the monoamine receptors, and 4) genetically removing the transporters or receptors for 
monoamines. None of these manipulations have resulted in a clear picture of how 
monoamines are involved in METH-induced hyperthermia, although some contribution is 
indicated. To further complicate the issue, most of these studies have not focused on METH 
hyperthermia per se, but are more concerned with the role of hyperthermia in promoting 
neurotoxicity (Albers & Sonsalla, 1995; Miller & O’Callaghan, 1994; Metzger et al., 2000). 
Certainly, the field would be served by a concerted effort to determine the causes of METH 
hyperthermia separate from the role this effect plays in METH neurotoxicity.
Although less well-studied than its effects on the CNS, METH also affects monoaminergic 
systems in the periphery. Reserpine, for example, is a vesicular monoamine transporter 
(VMAT) inhibitor that acts by depleting catecholamines from peripheral sympathetic nerve 
endings, causing vasodilation and a reduction in heart rate. It also lowers METH-induced 
elevations in core body temperature (Albers & Sonsalla, 1995; Ares-Santos et al., 2012), 
even causing hypothermia in some cases (Thomas et al., 2008). Consistent with the 
recognized actions of METH in the autonomic nervous system, peripheral chemical 
sympathectomy by 6-hydroxydopamine (OHDA) can completely block METH-induced 
hyperthermia (Makisumi et al., 1998), further supporting a role for peripheral monoamines 
in METH hyperthermia.
However, it should be noted that the contribution of catecholamines to METH hyperthermia 
can vary depending on species and environmental conditions. For example, depletion of 
catecholamines by pretreatment with α-methyl-p-tyrosine (AMPT), which inhibits tyrosine 
hydoxylase, the rate limiting enzyme in the biosynthetic pathway for catecholamines 
(dopamine, norepinephrine), can attenuate the hyperthermic effects of METH in rats, but not 
mice (Metzger et al., 2000; Sandoval et al., 2000; Thomas et al., 2008). In addition, the 
protective effects of AMPT in rats are observed at ambient room temperature, but not at an 
elevated room temperature (28.5° C) (Metzger et al., 2000). This suggests that 
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catecholamines may be important, but just one of the ways for METH to produce its 
hyperthermic effects.
In the sections that follow, efforts are made to summarize both peripheral and central effects 
of monoaminergic systems on body temperature changes. The sections are organized to first 
provide an overview of the effects of the neurotransmitter systems, with a focus on 
norepinephrine, dopamine, and serotonin, on thermoregulation in general, then followed by 
information with regard to their potential contributions to METH hyperthermia.
5.1.1 Norepinephrine systems—Activation of the hypothalamic-pituitary-adrenal 
(HPA) axis triggers the release of numerous hormones and neurotransmitters, including 
norepinephrine (Makisumi et al., 1998; Del Rios et al., 2005). In the CNS, the presence of 
α1-adrenoceptors on thermosensitive neurons in the medial preoptic anterior hypothalamus 
is noteworthy (Mallick et al., 2002). β-Adrenoceptors are also located in the hypothalamus 
(Reznikoff et al., 1986; Grimm et al., 1992) and have been implicated in thermoregulation 
(Docherty & Green, 2010). In the periphery, norepinephrine release triggers vasoconstriction 
and impaired heat dissipation via actions on adrenoceptors and also by uncoupling 
metabolism in thermogenic tissues (Morrison & Nakamura, 2011), further worsening 
hyperthermic events.
Pharmacological interventions that target specific aspects of adrenergic function in the 
context of METH-induced hyperthermia have received limited attention. The β-adrenoceptor 
antagonist, propranolol, is one of the few that has been reported to prevent METH-induced 
hyperthermia in laboratory mice (Albers & Sonsalla, 1995). Although the effects of 
antagonists for α1, α2A, and β3 receptors have been studied in the context of MDMA 
(Docherty & Green, 2010, Hysek et al., 2013), similar investigations with METH have yet to 
be performed.
Most of the manipulations that affect METH-induced noradrenergic function and body 
temperature have been relatively nonspecific. METH-induced increases in body temperature 
are prevented by 6-OHDA sympathectomy or adrenalectomy (Makisumi et al., 1998) by 
inhibiting the presumed release of norepinephine by METH. In adrenalectomized rats 
treated with dexamethasone, METH elicits hyperthermia, demonstrating modulation by 
glucocorticoids (Makisumi et al., 1998). Dantrolene, an inhibitor of sarcoplasmic reticulum 
calcium release in muscle, also prevents METH-induced hyperthermia (Makisumi et al., 
1998). Together, the data suggest that METH stimulates norepinephrine release from 
sympathetic nerve terminals, thereby enhancing thermogenesis in skeletal muscles under the 
permissive control of glucocorticoids (Makisumi et al., 1998). The adrenoceptor subtypes 
that mediate these effects remain to be determined.
5.1.2. Dopamine systems—Early studies have shown that direct injection of dopamine 
or the dopamine agonist, apomorphine, into the anterior preoptic area of the hypothalamus, 
caudate-putamen, or globus pallidus elicits hypothermia, whereas similar microinjections of 
dopamine antagonists (e.g., haloperidol, pimozide) produce hyperthermia (Lin et al., 1982). 
These dopamine-related changes in body temperature appear mediated through alterations in 
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metabolism and cutaneous blood flow, but not respiratory evaporative processes (Lin et al., 
1982).
METH can readily enter cells and facilitate the release of dopamine while simultaneously 
preventing reuptake, resulting in increased dopamine in the synaptic cleft (Davidson et al., 
2001; Krasnova & Cadet, 2009). However, in contrast to locally administered dopamine or a 
dopamine agonist into specific brain regions (Lin et al., 1982), METH-induced release of 
dopamine causes profound hyperthermia. These differences in response between direct 
application of dopamine or its agonists/antagonists to a given brain area and the METH-
induced hyperthermia suggest that the METH-induced changes in body temperature do not 
result from dopamine release in the specific areas of the brain characterized in the 
microinjections studies (e.g., anterior preoptic area of the hypothalamus, caudate-putamen, 
globus pallidus). Nevertheless, the activation of dopamine receptors (presumably in other 
regions of the body) appears to be a significant mediator of the hyperthermic effects of 
METH (Albers & Sonsalla, 1995; Funahashi et al., 1990; He et al., 2004; Broening et al., 
2005), as ample evidence summarized below suggests these effects can be mitigated through 
antagonism or knockout of dopamine receptors.
Numerous studies have shown, for example, that attenuation of dopamine D2 function using 
pharmacological or molecular biological tools can reduce the hyperthermic effects of 
METH. METH fails to elicit hyperthermia in dopamine D2 knockout mice (Ito et al., 2008; 
Granado et al., 2011). Likewise, the dopamine D2 antagonists, haloperidol and sulpiride, 
attenuate METH-induced hyperthermia in mice (Funahashi et al., 1990; Albers & Sonsalla, 
1995). The selective dopamine D2 antagonist, eticlopride, also mitigates the hyperthermic 
effects of METH at normal ambient temperature, but loses its protective effects at a higher 
ambient temperature (33° C) (Metzger et al., 2000; Broening et al., 2005); this suggests that 
D2 receptors alone are not sufficient for mediating heat dissipation under extreme 
conditions.
Although the magnitude of the effects does not appear as pronounced as for the D2 receptor, 
D1 receptors may also play an important role. The antipsychotic drug, risperidol, can 
mitigate the hyperthermia produced by METH when given as either a pre-treatment or post-
treatment; this effect is thought to be mediated through interactions with dopamine D1 
receptors (Shioda et al., 2010). It should be noted, however, that risperidol also has 5-HT2A 
receptor and anti-adrenergic activity, both of which may further assist in reducing the 
hyperthermic effects of METH (Shioda et al., 2010; Cohen, 1994). Further supporting the 
involvement of D1 receptors in the hyperthermic actions of METH, there is a significant 
reduction in the extent to which METH produces hyperthermia in mice lacking D1 receptors 
(Ito et al., 2008; Ares-Santos et al., 2012). Moreover, the D1 antagonist, SCH 23390, 
attenuates METH-induced hyperthermia (Broening et al., 2005). Similar to the effects seen 
with D2 antagonists, knockout and antagonism of D1 receptors loses their protective effects 
at higher ambient temperatures (29° C and 33° C, respectively) (Ares-Santos et al., 2012; 
Broening et al., 2005). One reason that elevated environmental temperatures may overcome 
the protective effects conveyed by dopamine antagonists at normal ambient temperatures 
may be that it can overcome the ability of the antagonists to dissipate heat through 
peripheral mechanisms under these conditions.
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Although there is general support for the involvement of dopamine D1 and D2 receptors in 
the hyperthermic effects of METH, exceptions have been reported. Raclopride (1 mg/kg) 
and SCH 23390 (0.1 mg/kg), D2 and D1 antagonists, respectively, did not attenuate the 
elevated body temperatures produced by a bolus dose of METH (30 mg/kg) in ICR mice; 
body temperature measurements were taken each hour and the selected doses were ones that 
protected against other neurotoxic endpoints of METH (Xu et al., 2005). The reason for this 
divergence in results from the overall pattern reported by others remains to be determined.
The hyperthermic effects of METH are believed to contribute to an increased risk of death. 
Therefore, it is noteworthy that in dopamine D1 and D2 knockout mice, there is also a 
reduction in lethality in addition to a reduction in hyperthermia produced by METH (Ito et 
al., 2008). Moreover, in both the knockout and wild-type groups, the METH-treated mice 
that survive have lower body temperatures than those that die (Ito et al., 2008).
In contrast to dopamine receptors, the dopamine transporter (DAT) appears to play a more 
limited role in mediating METH-induced changes in body temperature. In particular, DAT 
knockout mice show a modest, albeit insignificant, reduction in METH-induced 
hyperthermia as compared to wild-type controls (Numachi et al., 2007). The compromised 
ability of METH to fully elicit hyperthermia in the absence of DAT suggests some 
involvement of an increase in synaptic dopamine by METH in altering body temperature, 
but indicate that this is most likely not the primary cause of the hyperthermic effects. DAT 
knockout mice do, however, have a significantly higher LD50 for METH compared to wild-
type mice, supporting the importance of dopamine in the lethal effects of METH (Numachi 
et al., 2007).
Overall, the data indicate that the dopamine releasing actions of METH may contribute to 
hyperthermia, with dopamine antagonists capable of mitigating the elevations in body 
temperature. However, the blockade of hyperthermia may be incomplete under some 
conditions, suggesting the involvement of other contributing systems to the body 
temperature changes. Moreover, classical dopaminergic brain regions typically implicated in 
thermogenesis and psychostimulant actions (i.e., hypothalamus and striatum) may not be the 
principal site of action mediating the dopaminergic component of METH-induced 
hyperthermia.
5.1.3. Serotonin systems—Serotonergic pathways have been directly implicated in the 
central control of most forms of thermogenesis (Rothwell, 1994). Previous data have shown 
that changes in neuronal serotonin levels correlate with changes in brain and core body 
temperatures (Schwartz et al., 1995; Salmi & Ahlenius, 1998). Direct injection of serotonin 
into the anterior preoptic area of the hypothalamus or electrical stimulation of the dorsal 
raphe to release serotonin from the nerve terminals elicits hypothermia, whereas direct 
injection of serotonergic antagonists (e.g., methysergide, cyproheptadine) into this region 
produces hyperthermia; these changes in body temperature result from alterations in 
metabolism and vasodilation/constriction of the blood vessels in the skin (Lin et al., 1983). 
Activation of 5-HT1A and 5-HT3 receptors in the brain also elicits hypothermia (Voronova 
et al., 2011). Since the aforementioned antagonists (methysergide, cyproheptadine) attenuate 
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5-HT2 receptor signaling, it appears that multiple serotonin receptor subtypes participate in 
central thermoregulatory processes.
In contrast, systemic administration of a selective 5-HT2A receptor agonist elevates body 
temperature (Zhang & Tao, 2011). The hyperthermic effect of 5-HT2A agonists can be life 
threatening and has been attributed at least in some cases to activation of skeletal muscles 
(Loscher et al., 1990). In addition, peripheral effects of serotonin include the regulation of 
skin blood flow, which is a major mechanism involved in thermoregulation (Mauer-Spurej, 
2005).
As with the other studies investigating the role of monoamine systems in METH-induced 
hyperthermia, studies investigating the role of the serotonin system have examined how 
manipulations involving serotonin receptors, transporters and levels of the transmitter 
influence METH–induced hyperthermia. Commensurate with its actions on the other 
monoamines, METH facilitates serotonin release from the nerve terminal, inhibits the action 
of the rate-limiting enzyme, tryptophan hydroxylase, for the production of serotonin, inhibits 
its transport and causes its long term depletion in some instances (Kuczenski et al., 1995; 
Fukumura et al., 1998; Ago et al., 2006; Numachi et al., 2008). Reductions in brain 
serotonin effected by treating mice with p-chlorophenylalanine (PCPA), an irreversible 
inhibitor of tryptophan hydroxylase, the rate limiting enzyme in the biosynthesis of 
serotonin, attenuates METH-induced hyperthermia (Thomas et al., 2010). However, 
treatment of mice with tryptophan hydroxylase does not significantly alter the effects of 
METH on body temperature, and tryptophan hydroxylase 2 knockout mice which lack brain 
serotonin in fact exhibit an enhanced hyperthermic response of about 1°C to METH 
(Thomas et al., 2010). This suggests that when endogenous serotonin levels are reduced, the 
hyperthermic effects of METH can be inhibited, but if endogenous serotonin is unavailable, 
then other neurochemical systems may compensate which can result in a paradoxical 
enhancement of hyperthermia.
Recent studies in rats show that METH also produces significant dose dependent increases 
in plasma serotonin (Zolkowska et al., 2006; Rothman et al., 2008; Yubero-Lahoz et al., 
2012). Because platelets and neurons express the same serotonin transporter (SERT) protein 
(Lesch et al. 1993) and 99% of the circulating serotonin is stored in platelets (Zolkowska et 
al., 2006), the elevations in plasma serotonin may well be mediated, at least in part, via 
interactions of METH with these platelet SERT proteins (Zolkowska et al., 2006; Rothman 
et al., 2008; Yubero-Lahoz et al., 2012). The association between METH-induced plasma 
serotonin and body temperature changes was, however, not examined in these studies and 
remains to be investigated. Nevertheless, while the specific sites in the body that mediate 
this hyperthermic effect have yet to be determined, peripheral targets are likely involved 
since central activation of serotonin function tends to cause reductions in body temperature.
It should be noted, however, that SERT per se is unlikely to be a direct contributor to 
hyperthermia. METH-induced hyperthermia is not altered nor is basal temperature in mice 
lacking SERT (Numachi et al., 2007). However, in the absence of DAT, SERT can have a 
compensatory role which permits METH to exert at least some of its hyperthermic effects 
(Numachi et al., 2007).
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Other reports also suggest that blocking the actions of released serotonin can prevent 
elevations in body temperature (Azzaro & Rutledge, 1973; Ginawi et al., 2005). NAN-190, a 
5-HT1A receptor antagonist, blocks METH-induced increases in body temperature, while 
displaying no effects on its own (Ginawi et al., 2005). In contrast, 8-OH-DPAT, a 5-HT1A 
receptor agonist that on its own can produce hypothermia (Bristow et al., 1991), fails to 
attenuate METH-induced hyperthermia (Albers & Sonsalla, 1995).
Paradoxically, fenfluramine, which enhances serotonin function through multiple 
mechanisms, mitigates the hyperthermic effects of METH (Miller & O’Callaghan, 1994; 
Albers & Sonsalla, 1995). It, however, remains unclear why this serotonin indirect agonist 
function would inhibit METH-induced hyperthermia when all other serotonergic compounds 
that reduce the hyperthermic effects of METH inhibit serotonin function. Moreover, 
fenfluramine also enhances norepinephrine release (Rothman et al., 2003), suggesting that 
the protective effects of the drug against METH-induced hyperthermia involve targets other 
than its classical monoaminergic mechanisms.
In conclusion, the data as a whole suggest that serotonin systems can have a significant 
modulatory and compensatory role in the hyperthermic effects of METH. However, 
endogenous serotonin does not appear to be a requirement for METH to elicit hyperthermia.
5.2. Reactive species
In addition to modulating the monoaminergic systems, METH may cause increases in core 
body temperature through the induction of reactive oxygen and nitrogen species (ROS/RNS) 
within the CNS. Many studies have thus investigated the effects of antioxidant compounds 
and inhibitors of enzymes and proteins responsible for the production of these ROS/RNS in 
the CNS.
Pretreatment of rats with the ROS scavenger, α-tocopherol, attenuates METH-induced 
hyperthermia (Park et al., 2006). The pineal hormone, melatonin, also acts as a free radical 
scavenger and prevents METH-induced hyperthermia in mice (Itzhak et al., 1998).
The generation of hydroxyl radicals from H2O2 is catalyzed by iron via the Fenton reaction. 
The iron chelator, deferoxamine, which inhibits the generation of ROS, also significantly 
attenuates METH-induced hyperthermia in rats (Park et al., 2006).
Under normal conditions, nitric oxide synthase (NOS) catalyzes the formation of nitric oxide 
from L-arginine, and has an important role in vasodilation through the relaxation of smooth 
muscles. Under pathological conditions, NOS can also catalyze the production of the free 
radical, superoxide. 7-Nitroindazole is a neuronal NOS (nNOS) inhibitor that attenuates 
METH-induced elevations in body temperature at low ambient temperature (20° C; Callahan 
& Ricaurte, 1998), but not at normal ambient temperature (Itzhak & Ali, 1996), or at higher 
ambient temperature (28° C; Callahan & Ricaurte, 1998). Two other nNOS inhibitors, S-
methylthiocitrulline and 3-bromo-7-nitroindazole, also cannot block METH-induced 
hyperthermia at room temperature (Itzhak et al., 2000). However, nNOS knockout mice are 
resistant to the hyperthermic effects of METH, compared to wild-type mice (Itzhak et al., 
1998). Since free radicals are generated very quickly, it is possible that the interventions 
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produce measurable effects against METH-induced hyperthermia only when no catalyzing 
enzyme is present or the reactions are sufficiently slowed (e.g., by reducing temperature); 
when the reactions occur at a faster rate at higher temperatures, the intervention attempts 
may be overcome.
In addition to ROS, studies also suggest the involvement of peroxynitrite radicals in the 
hyperthermic effects of METH. The peroxynitrite catalyst, 5,10,15,20-tetrakis(N-methyl-4′-
pyridyl)porphyrinato iron III (FeTMPγP) protects against METH-induced hyperthermia in 
rodents (Imam et al., 1999). Moreover, compared to young rats, aged animals are more 
sensitive to METH-induced formation of peroxynitrite radicals and also exhibit increased 
sensitivity to the hyperthermic and lethal effects of METH (Imam et al., 2001). In contrast, 
the radical scavenger, edaravone, blocks peroxynitrite production, but cannot attenuate the 
hyperthermic effects of METH in mice (Kawasaki et al., 2006), underscoring the complexity 
of the relationship between METH, the generation of reactive species, and hyperthermia.
5.3. Immune system
Another potential mechanism by which METH is believed to cause hyperthermia is through 
increases in immune responses, such as cytokine release. These effects appear to be 
mediated primarily through peripheral, rather than central, mechanisms.
Systemic injections of interferon-γ significantly reduce METH-induced elevations in core 
body temperature (Hozumi et al., 2008); however, intracerebroventricular treatment has no 
significant effects on body temperature. These results imply that METH may be modulating 
immune system responses in the periphery, leading to alterations in body temperature.
Mithramycin is an FDA-approved immunosuppressive antibiotic with antitumor and 
neuroprotective actions (Gerber & Steinberg, 1976; Sleiman et al., 2011). It also attenuates 
METH-induced hyperthermia in laboratory animals (Hagiwara et al., 2009). Although the 
molecular mechanism underlying this protective effect has yet to be determined, 
mithramycin acts as an inhibitor of the specificity protein 1 (SP-1) family of transcription 
factors (Ray et al., 1989). Through this mechanism, mithramycin has been reported to 
abolish the induction of heat shock protein (HSP) 70 (Marinova et al., 2009) which can be 
activated by METH (Beauvais et al., 2011).
5.4. Miscellaneous mechanisms that affect METH hyperthermia
The activation of protein kinase Cδ (PKCδ), which can result from activation of 
dopaminergic neurotransmission, also appears to contribute to the hyperthermic effects of 
METH. Rottlerin, a PKCδ inhibitor, mitigates METH-induced hyperthermia (Shin et al., 
2011). It also attenuates the concomitant increases in brain PKCδ produced by METH (Shin 
et al., 2011). The potential importance of PKCδ in the hyperthermic effects of METH is also 
supported by the observation that PKCδ knockout mice are resistant to the hyperthermic 
effects of METH (Shin et al., 2011).
Sigma receptors also appear to play a role in the hyperthermic effects of METH. METH 
interacts with sigma receptors at micromolar concentrations that can be achieved under 
physiological conditions (Nguyen et al., 2005). These proteins are found in the 
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hypothalamus, as well as the cardiovascular system (McLean & Weber, 1988; Ela et al., 
1994; Zhang & Cuevas, 2002; Tagashira et al., 2010). Pretreatment of mice with selective 
sigma receptor putative antagonists, including AC927, AZ66, CM156, and SN79, 
significantly attenuates METH-induced hyperthermia (Matsumoto et al., 2008; Kaushal et 
al., 2011, 2013; Seminerio et al., 2012, 2013; Robson et al., 2013).
Another miscellaneous compound that has been reported to attenuate METH-induced 
hyperthermia, without significantly altering body temperature on its own, is phenytoin, an 
anticonvulsant drug (Albers & Sonsalla, 1995). In addition, the following compounds reduce 
METH-induced hyperthermia, but also produce hypothermia when administered alone: 
aminoxyacetic acid (AOAA), a GABA transaminase inhibitor (Albers & Sonsalla, 1995); 
MK-801, an N-methyl-D-aspartate (NMDA) receptor antagonist (Albers & Sonsalla, 1995); 
and ibogaine, an alkaloid shown to block many effects of abused substances (Yu et al., 
1999).
5.5. Mechanisms that do not affect METH hyperthermia
Many of the drugs that have been previously shown to have no significant effects on METH-
induced hyperthermia were initially tested due to their fever-reducing, anti-inflammatory, 
and/or neuroprotective effects. These compounds and mechanisms are briefly summarized in 
this section and underscore the differences between the pathophysiology and clinical 
manifestations of hyperthermia vs. fever (McAllen & Schwartz, 2010). It also serves as a 
reminder that neuroprotection can be achieved through temperature-independent 
mechanisms.
Non-steroidal anti-inflammatory drugs (NSAIDs) do not have significant effects on METH-
induced hyperthermia. In mice, pretreatment with ibuprofen or aspirin has been confirmed to 
have no effect on METH-induced hyperthermia (Albers & Sonsalla, 1995; Tsuji et al., 
2009).
Similarly, an interleukin-1 (IL-1) receptor antagonist failed to have significant effects on 
METH-induced hyperthermia in rodents, although it did reduce deaths (Bowyer et al., 
1994). Although IL-1 and related family members are known pyrogens (Kluger, 1991; Leon, 
2002) whose expression is increased in the hypothalamus following METH (Bandtlow et al., 
1990; Yamaguchi et al., 1991; Bowyer et al., 1994), their expression levels are not 
correlated with the body temperatures of the animals (Seminerio et al., 2012). Moreover, 
pharmacological intervention is capable of preventing the hyperthermic response to METH 
in the presence of increases in hypothalamic IL-1β expression (Seminerio et al., 2012).
A number of neuroprotective agents and genetic modifications that were tested primarily to 
determine their effects on METH-induced neurotoxicity, were shown to lack significant 
effects on METH-induced hyperthermia. They include: edaravone, a pharmaceutical product 
available in Japan indicated for ischemia related to acute ischemic stroke (Kawasaki et al., 
2006); carnosine, an endogenous antioxidant available in several over-the-counter dietary 
supplements (Pubill et al., 2002); minocycline, a second generation tetracycline antibiotic 
that crosses the blood brain barrier to elicit neuroprotective and anti-inflammatory effects in 
animals models (Zhang et al., 2006); memantine, an NMDA antagonist used in Europe for 
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the treatment of neurodegenerative disorders (Chipana et al., 2008); methylcaconitine, an 
α7-nicotinic acetylcholine receptor antagonist that inhibits METH-induced ROS production 
in rat synaptosomes (Escubedo et al., 2005); calcitriol, a vitamin D metabolite and 
neuroprotective agent (Cass et al., 2006); ketamine, a dissociative anesthetic (Ke et al., 
2008); and interleukin-6 knockout mice (Ladenheim et al., 2000).
6. Summary and conclusions
METH elicits elevations in body temperature, with high doses causing hyperthermia, which 
can be life threatening. Clinically, the hyperthermic effects of METH are treated 
symptomatically by cooling. No specific pharmacotherapy currently is indicated for treating 
the hyperthermic effects of METH. This situation is not surprising given that no 
pharmacological profile exists for protecting against METH-induced hyperthermia because 
no single mechanism has been identified underlying the hyperthermic actions of METH. 
Rather, multiple systems appear to contribute to the elevations in body temperature. While 
there has been an emphasis on drugs affecting monoaminergic systems as a means to lower 
METH-related hyperthermia, as we note above, this stems from the historical basis of 
METH actions on monoaminergic neurotransmitters rather than a solid scientific basis for 
drug interventions targeting a specific monoamine-related temperature mechanism. Indeed, 
we note that broad classes of pharmacological agents, with no clear mechanistic effects on 
thermoregulation (e.g. Miller & O’Callaghan, 1994), all may serve as effective 
countermeasures against METH-induced hyperthermia.
While much is known about the mechanisms that regulate thermal physiology in response to 
hot and cold ambient environments, the basis for the hyperthermic effects of METH remain 
largely unknown and relatively unexplored. Most animal studies to date have employed 
systemic administration of drugs or genetic knockouts to evaluate their effects on METH, 
making it difficult to conclusively attribute changes to central and/or peripheral sites of 
action. The few studies that have attempted to do so suggest the importance of peripheral 
mechanisms, often implicating the ability of the manipulation to affect heat generation 
within muscle. In that regard, noradrenergic effects in the sympathetic nervous system 
appear important in mediating METH-induced hyperthermia. Therefore, further 
investigations into the involvement of specific subtypes of adrenoceptors, particular those 
that preferentially act in the periphery, would be of value. In addition, studies examining the 
involvement of peripheral serotonin in mediating the hyperthermic effects of METH are 
greatly needed.
A wide variety of targets and mechanisms have been implicated in the hyperthermic effects 
of METH, beyond involvement of a limited number of neurotransmitter systems. These 
include the blood brain barrier, choroid plexus, meninges-associated vasculature (Kiyatkin 
& Sharma, 2009; Bowyer et al., 2013) and glial as well as neuronal mechanisms (Kiyatkin 
& Sharma, 2011). Indeed, as sources of proinflammatory mediators, some potentially 
involved in temperature regulation, astrocytes and microglia represent overlooked players in 
METH actions related to hyperthermia.
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While assumptions have been made to suggest that METH hyperthermia operates through 
disruption in known thermoregulatory mechanisms, there is little data to support this notion. 
Most studies to date have focused on mediators previously implicated in fever with modest 
success, and those that convey neuroprotective actions have provided only slightly more 
insight. Given the lack of clear avenues of investigation to pursue to achieve an 
understanding of METH-induced hyperthermia and its treatment, a more global exploration 
might be of benefit. In that regard, genome-wide array studies of multiple organs (not just 
brain) following hyperthermia instigated by elevations in ambient temperature vs. METH-
induced hyperthermia might reveal genes and networks involved in mediating elevated 
temperatures under these two conditions and, hopefully, point to targets for therapeutic 
intervention.
Health-related complications resulting from METH abuse remains a significant worldwide 
public health problem. Further studies to better understand the pathophysiology of METH-
induced hyperthermia are clearly needed to delineate the molecular mechanisms and 
biological systems that contribute to it. This information will be critical for developing 
effective therapeutic interventions to assist in the treatment of this potentially life 
threatening condition.
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Methamphetamine causes hyperthermia through a variety of mechanisms involving 
numerous systems. Methamphetamine causes neurotransmitter release and increased 
metabolism in the central nervous system (CNS). Additionally, methamphetamine can 
increase heart rate and result in hyperactivity, leading to increased heat production in the 
periphery. Vasoconstriction is another consequence of methamphetamine exposure, which 
results in a decreased ability of the body to rid itself of the increased heat resulting from 
these effects.
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Table 1
Physiological responses to environmental heat vs. methamphetamine.
Exposure to high ambient temperature Exposure to high dose methamphetamine
1) Increase in blood and brain temperature 1) Increase in brain temperature
2) Hypothalamic response:
• Activation of heat sensitive neurons in preoptic area of the 
hypothalamus
• Activation of anterior hypothalamus
2) Hypothalamic response:
• Increase in heat shock protein (HSP) expression
3) Activation of heat loss mechanisms:
• Decrease in metabolic activity
• Decrease in muscle activity
• Increase in blood circulating through skin
• Increase in sweating
3) Activation of heat production mechanisms:
• Vasoconstriction
• Piloerection in animals
4) Activation of heat loss mechanisms:
• Saliva spreading in animals
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